1. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives.
Lancet 2013;382:260–272.
2. Park S, Lee S, Kim Y, et al. Reduced risk for chronic kidney disease after recovery from metabolic syndrome: a nationwide population-based study.
Kidney Res Clin Pract 2020;39:180–191.
3. Ikizler TA, Burrowes JD, Byham-Gray LD, et al. KDOQI clinical practice guideline for nutrition in CKD: 2020 update.
Am J Kidney Dis 2020;76(3 Suppl 1):S1–S107.
4. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation.
Am J Kidney Dis 2000;35(6 Suppl 2):S17–S104.
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3:1–150.
7. Sasaki S. Preface: evidence-based practice guideline for the treatment of chronic kidney disease.
Clin Exp Nephrol 2009;13:533.
8. Japanese Society of Nephrology. Essential points from evidence-based clinical practice guidelines for chronic kidney disease 2018.
Clin Exp Nephrol 2019;23:1–15.
9. Shemin D, Dworkin LD. Sodium balance in renal failure.
Curr Opin Nephrol Hypertens 1997;6:128–132.
10. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease.
Kidney Int 2021;99(3S):S1–S87.
11. Kistler BM, Moore LW, Benner D, et al. The International Society of Renal Nutrition and Metabolism commentary on the National Kidney Foundation and Academy of Nutrition and Dietetics KDOQI clinical practice guideline for nutrition in chronic kidney disease.
J Ren Nutr 2021;31:116–120.
12. Kistler BM, Benner D, Burrowes JD, et al. Eating during hemodialysis treatment: a consensus statement from the International Society of Renal Nutrition and Metabolism.
J Ren Nutr 2018;28:4–12.
13. Iseki K, Yamagata K. A practical approach of salt and protein restriction for CKD patients in Japan.
BMC Nephrol 2016;17:87.
14. Wakasugi M, James Kazama J, Narita I. Associations between the intake of miso soup and Japanese pickles and the estimated 24-hour urinary sodium excretion: a population-based cross-sectional study.
Intern Med 2015;54:903–910.
15. Yazaki Y, Kadowaki T. Combating diabetes and obesity in Japan.
Nat Med 2006;12:73–74.
16. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.
Circulation 2009;120:1640–1645.
17. Kohro T, Furui Y, Mitsutake N, et al. The Japanese national health screening and intervention program aimed at preventing worsening of the metabolic syndrome.
Int Heart J 2008;49:193–203.
18. Ninomiya T, Kiyohara Y, Kubo M, et al. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study.
Am J Kidney Dis 2006;48:383–391.
19. Tozawa M, Iseki C, Tokashiki K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults.
Hypertens Res 2007;30:937–943.
20. Iseki K. Metabolic syndrome and chronic kidney disease: a Japanese perspective on a worldwide problem.
J Nephrol 2008;21:305–312.
21. Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study.
Kidney Int 2007;71:159–166.
22. Ohta Y, Tsuchihashi T, Kiyohara K, Oniki H. High salt intake promotes a decline in renal function in hypertensive patients: a 10-year observational study.
Hypertens Res 2013;36:172–176.
23. Sugiura T, Takase H, Ohte N, Dohi Y. Dietary salt intake is a significant determinant of impaired kidney function in the general population.
Kidney Blood Press Res 2018;43:1245–1254.
24. Kelly JT, Su G, Zhang L, et al. Modifiable lifestyle factors for primary prevention of CKD: a systematic review and meta-analysis.
J Am Soc Nephrol 2021;32:239–253.
25. Yano Y, Fujimoto S, Sato Y, et al. Association between prehypertension and chronic kidney disease in the Japanese general population.
Kidney Int 2012;81:293–299.
26. Iseki K, Asahi K, Moriyama T, et al. Risk factor profiles based on estimated glomerular filtration rate and dipstick proteinuria among participants of the Specific Health Check and Guidance System in Japan 2008.
Clin Exp Nephrol 2012;16:244–249.
27. Iseki K, Konta T, Asahi K, et al. Dipstick proteinuria and all-cause mortality among the general population.
Clin Exp Nephrol 2018;22:1331–1340.
28. Wakasugi M, Kazama J, Narita I, et al. Association between overall lifestyle changes and the incidence of proteinuria: a population-based, cohort study.
Intern Med 2017;56:1475–1484.
29. Kudo A, Asahi K, Satoh H, et al. Fast eating is a strong risk factor for new-onset diabetes among the Japanese general population.
Sci Rep 2019;9:8210.
30. Yoon CY, Noh J, Lee J, et al. High and low sodium intakes are associated with incident chronic kidney disease in patients with normal renal function and hypertension.
Kidney Int 2018;93:921–931.
31. DiNicolantonio JJ, Niazi AK, Sadaf R, O’ Keefe JH, Lucan SC, Lavie CJ. Dietary sodium restriction: take it with a grain of salt.
Am J Med 2013;126:951–955.
32. Ritz E, Schwenger V. Lifestyle modification and progressive renal failure.
Nephrology (Carlton) 2005;10:387–392.
33. de Francisco AL, Fresnedo GF, Palomar R, Piñera C, Arias M. The renal benefits of a healthy lifestyle.
Kidney Int Suppl 2005;99:S2–S6.
34. Iseki K, Tohyama K, Matsumoto T, Nakamura H. High prevalence of chronic kidney disease among patients with sleep related breathing disorder (SRBD).
Hypertens Res 2008;31:249–255.
35. Sakaguchi Y, Shoji T, Kawabata H, et al. High prevalence of obstructive sleep apnea and its association with renal function among nondialysis chronic kidney disease patients in Japan: a cross-sectional study.
Clin J Am Soc Nephrol 2011;6:995–1000.
36. Sakaguchi Y, Hatta T, Hayashi T, et al. Association of nocturnal hypoxemia with progression of CKD.
Clin J Am Soc Nephrol 2013;8:1502–1507.
37. Nakamura K, Nakamura H, Tohyama K, et al. Survival benefit of continuous positive airway pressure in Japanese patients with obstructive sleep apnea: a propensity-score matching analysis.
J Clin Sleep Med 2021;17:211–218.
38. Iseki K; for the Okinawa Dialysis Study (OKIDS) Group. Analysis of referral pattern and survival in chronic dialysis patients in Okinawa, Japan (1993–1997).
Clin Exp Nephrol 2002;6:43–48.
39. Sprangers B, Evenepoel P, Vanrenterghem Y. Late referral of patients with chronic kidney disease: no time to waste.
Mayo Clin Proc 2006;81:1487–1494.
40. Campbell GA, Bolton WK. Referral and comanagement of the patient with CKD.
Adv Chronic Kidney Dis 2011;18:420–427.
41. Rysz J, Franczyk B, Ławiński J, Olszewski R, Ciałkowska-Rysz A, Gluba-Brzózka A. The impact of CKD on uremic toxins and gut microbiota.
Toxins (Basel) 2021;13:252.
42. Sumida K, Kovesdy CP. The gut-kidney-heart axis in chronic kidney disease.
Physiol Int 2019;106:195–206.
43. Sumida K, Molnar MZ, Potukuchi PK, et al. Constipation and Incident CKD.
J Am Soc Nephrol 2017;28:1248–1258.
44. Sofue T, Okano Y, Matsushita N, et al. The effects of a participatory structured group educational program on the development of CKD: a population-based study.
Clin Exp Nephrol 2019;23:1031–1038.
45. Niu SF, Wu CK, Chuang NC, Yang YB, Chang TH. Early Chronic Kidney Disease Care Programme delays kidney function deterioration in patients with stage I-IIIa chronic kidney disease: an observational cohort study in Taiwan.
BMJ Open 2021;11:e041210.
46. Oellgaard J, Gæde P, Rossing P, Persson F, Parving HH, Pedersen O. Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits.
Kidney Int 2017;91:982–988.
47. Navaneethan SD, Zoungas S, Caramori ML, et al. Diabetes management in chronic kidney disease: synopsis of the 2020 KDIGO Clinical Practice Guideline.
Ann Intern Med 2021;174:385–394.
48. Yamagata K, Makino H, Iseki K, et al. Effect of behavior modification on outcome in early- to moderate-stage chronic kidney disease: a cluster-randomized trial.
PLoS One 2016;11:e0151422.
49. Hoshino J, Nagai K, Kai H, et al. A nationwide prospective cohort study of patients with advanced chronic kidney disease in Japan: the Reach-J CKD cohort study.
Clin Exp Nephrol 2018;22:309–317.
50. Okubo R, Kondo M, Hoshi SL, et al. Cost-effectiveness of behavior modification intervention for patients with chronic kidney disease in the FROM-J Study.
J Ren Nutr 2021;31:484–493.
51. McMahon EJ, Campbell KL, Bauer JD. Taste perception in kidney disease and relationship to dietary sodium intake.
Appetite 2014;83:236–241.
52. Kang M, Kang E, Ryu H, et al. Measured sodium excretion is associated with CKD progression: results from the KNOW-CKD study.
Nephrol Dial Transplant 2021;36:512–519.
53. Garofalo C, Provenzano M, Andreucci M, et al. Predictive effect of salt intake on patient and kidney survival in non-dialysis CKD: competing risk analysis in older versus younger patients under nephrology care.
Nephrol Dial Transplant 2021;36:2232–2240.
54. Himmelfarb J, Vanholder R, Mehrotra R, Tonelli M. The current and future landscape of dialysis.
Nat Rev Nephrol 2020;16:573–585.
55. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis.
N Engl J Med 2002;347:2010–2019.
56. Twardowski ZJ, Misra M, Singh AK. Con: Randomized controlled trials (RCT) have failed in the study of dialysis methods.
Nephrol Dial Transplant 2013;28:826–832.
57. Singh AK, Kari JA, Twardowski ZJ, Misra M. Pro: The value of randomized controlled studies in dialysis methods.
Nephrol Dial Transplant 2013;28:834–836.
58. Van Biesen W, Lameire N. Moderator’s view: Are alternative dialysis strategies superior to conventional dialysis: what Popper tells us.
Nephrol Dial Transplant 2013;28:837–838.
59. Goodkin DA, Young EW, Kurokawa K, Prütz KG, Levin NW. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects.
Am J Kidney Dis 2004;44(5 Suppl 2):16–21.
60. Kalantar-Zadeh K, Wightman A, Liao S. Ensuring choice for people with kidney failure: dialysis, supportive care, and hope.
N Engl J Med 2020;383:99.
61. Fernández-Martín JL, Martínez-Camblor P, Dionisi MP, et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.
Nephrol Dial Transplant 2015;30:1542–1551.
62. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease.
Kidney Int 2008;73:391–398.
63. Kalantar-Zadeh K, Fouque D. Nutritional management of chronic kidney disease.
N Engl J Med 2017;377:1765–1776.
64. Koppe L, Fouque D, Kalantar-Zadeh K. Kidney cachexia or protein-energy wasting in chronic kidney disease: facts and numbers.
J Cachexia Sarcopenia Muscle 2019;10:479–484.
65. Iseki K, Kawazoe N, Fukiyama K. Serum albumin is a strong predictor of death in chronic dialysis patients.
Kidney Int 1993;44:115–119.
66. Iseki K, Arima H, Kohagura K, et al. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial.
Nephrol Dial Transplant 2013;28:1579–1589.
67. Moromizato T, Kohagura K, Tokuyama K, et al. Predictors of survival in chronic hemodialysis patients: a 10-year longitudinal follow-up analysis.
Am J Nephrol 2021;52:108–118.
68. Tozawa M, Iseki K, Iseki C, Morita O, Yoshi S, Fukiyama K. Seasonal blood pressure and body weight variation in patients on chronic hemodialysis.
Am J Nephrol 1999;19:660–667.
69. Iseki K, Osawa A, Fukiyama K. Evidence for increased cancer deaths in chronic dialysis patients.
Am J Kidney Dis 1993;22:308–313.
70. Kanda E, Lopes MB, Tsuruya K, et al. The combination of malnutrition-inflammation and functional status limitations is associated with mortality in hemodialysis patients.
Sci Rep 2021;11:1582.
71. Kimura G, Kojima S, Saito F, et al. Quantitative estimation of dietary intake in patients on hemodialysis.
Int J Artif Organs 1988;11:161–168.
72. Ramdeen G, Tzamaloukas AH, Malhotra D, Leger A, Murata GH. Estimates of interdialytic sodium and water intake based on the balance principle: differences between nondiabetic and diabetic subjects on hemodialysis.
ASAIO J 1998;44:812–817.
73. Ikenoue T, Koike K, Fukuma S, Ogata S, Iseki K, Fukuhara S. Salt intake and all-cause mortality in hemodialysis patients.
Am J Nephrol 2018;48:87–95.
74. Dong J, Li Y, Yang Z, Luo J. Low dietary sodium intake increases the death risk in peritoneal dialysis.
Clin J Am Soc Nephrol 2010;5:240–247.
75. Dasgupta I, Thomas GN, Clarke J, et al. Associations between hemodialysis facility practices to manage fluid volume and intradialytic hypotension and patient outcomes.
Clin J Am Soc Nephrol 2019;14:385–393.
76. Sato Y, Toida T, Nakagawa H, et al. Diminishing dry weight is strongly associated with all-cause mortality among long-term maintenance prevalent dialysis patients.
PLoS One 2018;13:e0203060.
77. Kalantar-Zadeh K, Streja E, Molnar MZ, et al. Mortality prediction by surrogates of body composition: an examination of the obesity paradox in hemodialysis patients using composite ranking score analysis.
Am J Epidemiol 2012;175:793–803.
78. Siga MM, Ducher M, Florens N, et al. Prediction of all-cause mortality in haemodialysis patients using a Bayesian network.
Nephrol Dial Transplant 2020;35:1420–1425.
79. Brown IJ, Tzoulaki I, Candeias V, Elliott P. Salt intakes around the world: implications for public health.
Int J Epidemiol 2009;38:791–813.
80. Kimura Y, Yamamoto R, Shinzawa M, et al. Alcohol consumption and incidence of proteinuria: a retrospective cohort study.
Clin Exp Nephrol 2018;22:1133–1142.
81. Joo YS, Koh H, Nam KH, et al. Alcohol consumption and progression of chronic kidney disease: results from the Korean Cohort Study for Outcome in Patients with Chronic Kidney Disease.
Mayo Clin Proc 2020;95:293–305.
82. Yasutake K, Nagafuchi M, Tanaka T, et al. Necessity of salt intake reduction education beginning in youth: a cross-sectional survey of sodium-to-potassium ratios in mothers and their preschool children.
Hypertens Res 2021;44:1307–1315.
83. Tsuchihashi T, Ishimitsu T, Ando K, et al. JSH Statement: Tokyo declaration promoting salt reduction by the Japanese Society of Hypertension-the JSH Tokyo declaration.
Hypertens Res 2020;43:1133–1134.
84. Tsuchihashi T. Practical and personal education of dietary therapy in hypertensive patients.
Hypertens Res 2020;43:6–12.
85. Ueki K, Sasako T, Kato M, et al. Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial.
BMJ Open Diabetes Res Care 2016;4:e000123.
86. Ueki K, Sasako T, Okazaki Y, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial.
Lancet Diabetes Endocrinol 2017;5:951–964.
87. Iseki K, Kohagura K, Sakima A, et al. Changes in the demographics and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2003).
Hypertens Res 2007;30:55–62.
88. Usami T, Koyama K, Takeuchi O, Morozumi K, Kimura G. Regional variations in the incidence of end-stage renal failure in Japan.
JAMA 2000;284:2622–2624.
89. Silvariño R, Rios P, Baldovinos G, et al. Is chronic kidney disease progression influenced by the type of renin-angiotensin-system blocker used?
Nephron 2019;143:100–107.
90. McCoy IE, Han J, Montez-Rath ME, Chertow GM. Barriers to ACEI/ARB use in proteinuric chronic kidney disease: an observational study.
Mayo Clin Proc 2021;96:2114–2122.
91. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.
N Engl J Med 2015;373:2117–2128.
92. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease.
N Engl J Med 2020;383:1436–1446.
93. Foti KE, Wang D, Chang AR, et al. Potential implications of the 2021 KDIGO blood pressure guideline for adults with chronic kidney disease in the United States.
Kidney Int 2021;99:686–695.
94. McMahon EJ, Campbell KL, Bauer JD, Mudge DW, Kelly JT. Altered dietary salt intake for people with chronic kidney disease.
Cochrane Database Syst Rev 2021;6:CD010070.
95. Jain N, Reilly RF. Effects of dietary interventions on incidence and progression of CKD.
Nat Rev Nephrol 2014;10:712–724.
96. Garofalo C, Borrelli S, Provenzano M, et al. Dietary salt restriction in chronic kidney disease: a meta-analysis of randomized clinical trials.
Nutrients 2018;10:732.
97. Wang AY, Kalantar-Zadeh K, Fouque D, et al. Precision medicine for nutritional management in end-stage kidney disease and transition to dialysis.
Semin Nephrol 2018;38:383–396.
98. Kim SM, Jung JY. Nutritional management in patients with chronic kidney disease.
Korean J Intern Med 2020;35:1279–1290.
99. Kim Y, Park CW. Can management of the components of metabolic syndrome modify the course of chronic kidney disease?
Kidney Res Clin Pract 2020;39:118–120.